Interim leader named for FDA's generic drug office

03/20/2013 | Drug Store News · Reuters

The FDA has appointed Dr. Kathleen Uhl as acting director of the Office of Generic Drugs. "Dr. Uhl brings a wealth of regulatory and medical policy, scientific, and management experience to the position," Center for Drug Evaluation and Research Director Dr. Janet Woodcock wrote in a memo. Uhl previously was senior adviser to Dr. Greg Geba, who stepped down last week.

View Full Article in:

Drug Store News · Reuters

Published in Briefs: